| Literature DB >> 18293907 |
Ahcène Boumendjel1, Julien Boccard, Pierre-Alain Carrupt, Edwige Nicolle, Madeleine Blanc, Annabelle Geze, Luc Choisnard, Denis Wouessidjewe, Eva-Laure Matera, Charles Dumontet.
Abstract
A series of 59 chalcones was prepared and evaluated for the antimitotic effect against K562 leukemia cells. The most active chalcones were evaluated for their antiproliferative activity against a panel of 11 human and murine cell cancer lines. We found that three chalcones were of great interest as potential antimitotic drugs. In vivo safety studies conducted on one of the most active chalcones revealed that the compound was safe, allowing further in vivo antitumor evaluation.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18293907 DOI： 10.1021/jm0708331
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446